What Germany Got Right in Medical Innovation: From Historical Setbacks to European Leadership

This stems from the United States' former“Educational Background”This can be verified. According to statistics, before World War I,Approximately 10,000 Americans travel to Germany for study each year., far exceeding the combined total of those who went to the United Kingdom and France; the primary purpose of these “international students” was to learn Germany’s advanced medical technologies.

But the good times did not last long. After World War II, Germany encountered its “Waterloo” in the field of medical innovation. On one hand, there was a massive “brain drain” of scientists from Germany’s domestic medical sector; the United States alone absorbed“Abducted” nearly 400 of Germany’s top scientists; on the other hand, the United Nations imposed a “ten-year ban on scientific research” on the defeated nations, which left Germany in the medical fieldInnovation has long remained absent, the mature scientific research system is gradually collapsing, and the decline continues to deepen.

However, Germany did not collapse as a result; instead,“Ten-Year Research Ban”After Completion, leveraging its initial capital accumulation and substantial investments in medical innovation, Germany quickly caught up and regained its position among the global leaders in medical innovation, with its hard power second only to that of the United States.

Currently, Germany has become the center of Europe’s medical innovation industry, boasting a complete medical innovation chain. This is supported on one hand by “soft power” such as favorable policies and an innovative environment, and on the other hand by “hardware” including advanced medical research institutes, treatment technologies, and medical facilities. It is precisely based on this thatThe number and scale of German medical technology startups are increasing year by year.

So, what kind of innovation chain has Germany established in the healthcare sector? How has it managed to stand out in the fiercely competitive global market for medical innovation? What insights can this offer for China’s own efforts in healthcare innovation? To answer these questions,VCBeat Orange BureauIn-depth Analysis of Germany’s Path to Medical Innovation

To Europeans, Germany is an extremely “calm” country, with this “calmness” primarily referring toThe Rigorous and Steady Character of the Germans。

This is clearly reflected in German grammar. The rules of German grammar are quite rigid, with gender, number, and case following highly orderly patterns; sentence structures are fixed and cannot be arbitrarily rearranged or altered. This linguistic habit has fostered a “serious” character among Germans, who approach tasks in a methodical and disciplined manner, demonstrating logical and meticulous thinking that surpasses that of most other nations. Paradoxically, this gives Germans an inherent advantage in scientific research.

Paradoxically, while Germans are known for their calm demeanor, their enthusiasm for innovation is boundlessly intense. According to data from 2019,Germany's R&D investment amounted to $131.9 billion., accounting for more than 30% of the total in Europe.

In addition, regarding R&D intensity (the ratio of domestic R&D expenditure to GDP), data published by the OECD in 2021 show thatGermany’s R&D intensity stands at 3.2%, ranking ahead of the United States, China, and Japan, and nearly 1.1 percentage points higher than the European average.

It is evident from these data that Germans truly “love” scientific research; indeed, it is precisely their emphasis on research that has enabled them to repeatedly stand at the forefront of global science and technology.

Late 19th Century, King of PrussiaWilliam IIRecognizing that the nation’s backwardness stemmed from a shortage of talent and advanced technology, it began establishing modern universities across China, focusing not only on talent development but also on in-depth research and development of cutting-edge technologies.

After nearly a decade of accumulation, by the early 20th century, Germany had gradually joined the ranks of the world’s leading nations in scientific and technological development. During this period, numerous top-tier scientists and cutting-edge innovative achievements emerged, which, to some extent, bolstered Germany’s confidence in later launching World War II.

However, with Germany’s defeat in World War II, its economic and social development suffered a devastating blow, causing its accumulated scientific research achievements to come to naught, as a large number of scientists fled overseas, and because“The ten-year ban on scientific research” led to the gradual collapse of its stable and well-established research system, and its technological level was quickly surpassed by major powers such as the United States, the United Kingdom, and the former Soviet Union.

But the Germans did not give up because of this. After World War IIThe German government attaches great importance to the recovery and development of scientific and technological innovation, with a particular emphasis on integrating industrial foundations with technological innovation. Following the reunification of East and West Germany, the German government formulated a series of strategic plans to promote scientific and technological innovation, supported by complementary policies, continuously increased investment in science and technology, and established comprehensive systems for scientific and technological management and research and development.

Afterward, with theEUFollowing its establishment, Germany, which had gradually achieved a “recovery” in scientific research, began to further expand its research capabilities, engage in extensive and in-depth scientific and technological cooperation with other European countries, and gradually emerged as the scientific and technological hub of Europe.

The rapid advancement of scientific and technological innovation has quickly extended into the healthcare sector, leading to the gradual maturation of Germany’s medical innovation ecosystem. In response, the German Federal Ministry of Education and Research launched“German Bioregion Initiative”, a networked layout has been established across Germany, positioning medical innovation as a national strategic priority. Supported by this national initiative, numerous incubators and industrial parks have been developed in clusters where research institutions and industrial partners converge, such as BioM, Medical Valley, and BioTOP, thereby laying a more solid foundation for Germany’s medical innovation industry.

Apart from its large German population, Germany is home to the second-largest number of research institutions.

It is reported that Germany currently boasts the world’s densest network of research institutions and higher education establishments, along with a comprehensive scientific research system. First, in terms of higher education institutions, Germany has nearlyMore than 400 institutions of higher learning, including nearly 120 comprehensive universities (covering general studies, science and engineering, teacher training, etc.) and more than 220 universities of applied sciences.

Secondly, from the perspective of research institutions, Germany has renownedThe Four Major Scientific Associations (Max Planck Society, Fraunhofer Society, Helmholtz Association, Leibniz Association), as well as renowned institutions such as the German National Academy of Sciences Leopoldina, the Union of the German Academies of Sciences and Humanities, the Young Academy, and the National Academy of Science and Engineering.

From the perspective of funding sources, Germany has both universities, associations, and renowned academies supported by public funds, as well as industry-led research organizations such as the Industrial Research Association (AIF) backed by the private sector.

Finally, in terms of research scope, various research institutions cover all aspects from basic to applied research, forming a complex and rigorous network system of scientific research organizations. This ensures that Germany remains at the forefront of the world in basic scientific research, technological innovation, and industrial fields.

Among these, the most prominent are Germany’s four major national non-university research organizations—the Helmholtz Association, the Max Planck Society, the Fraunhofer Society, and the Leibniz Association—which symbolize Germany’s cutting-edge scientific research.

These “four pillars” have made invaluable contributions to technological innovation, serving not only as Germany’s most important scientific research force in foundational and frontier fields but also as the primary undertakers of national long-term strategic key basic research projects.

So, what exactly sets these four major research institutions apart?

Helmholtz AssociationTotal18 Independent Technology Centers, each center focuses on a different niche and has its own"Five-Year Performance Goals"The five-year assessment cycle was adopted to fully account for the long-term nature of scientific research. Additionally, in terms of securing research funding, the Helmholtz Association has formulated“Act within your limits”principle, whereby science and technology centers compete fairly with one another based on their own capabilities and proposed plans to secure state-funded research grants.

In addition,Helmholtz Associationalso veryEmphasize close collaboration with external innovation forces in research project partnerships, research infrastructure development, talent cultivation, and commercialization of research outcomes., the Helmholtz Association has extensive collaborations with external partners.

The Max Planck Society, officially known as the Max-Planck-Gesellschaft and commonly referred to as the Max Planck Society, was the first to be established among Germany’s “Four Great Research Institutions” and served as a critical springboard for the rapid post-World War II recovery of Germany’s scientific research capabilities.

The Max Planck Society focuses on basic research, typically employing an interdisciplinary approach to investigate issues in the fields of life sciences, natural sciences, and humanities and social sciences. It is reported that the Max Planck Society currentlyWith 84 research institutes, with 4,500 research projects across 120 countries, nearly 23,000 staff members, and approximately 6,500 scientists, nearly half of whom are international talents. Notably, since its establishment in 1948, 18 scientists from the Max Planck Society have been awarded the Nobel Prize.

The Max Planck Society aims to recruit the world’s most outstanding and creative scientists. Therefore, its core principle is to ensure absolute freedom in research, meaning that scientists are provided with optimal working conditions and have the autonomy to freely select their staff, research topics, and collaborators. It is precisely on this basis that the Max Planck Society has attracted numerous top-tier international participants, with over 70% of its postdoctoral researchers holding foreign passports.

The Fraunhofer Society was established in 1949 and isEurope’s largest applied science research organization, currently comprising 81 independent research institutes, with over 29,000 employees and an annual budget of up to €2 billion (equivalent to RMB 14.3 billion).

The Fraunhofer Society is positioned in applied research,Deeply focusing on key future-oriented technologies and the development of commercial outcomes. The association effectively serves as a “bridge” between academic research and industrial production., closely linking higher education institutions engaged in basic research with enterprises involved in product development to form synergies and jointly promote industrial innovation and translation.

As of April 2020, the Fraunhofer Society had a total ofNumber of Patents: 13,942. This is consistent with its possession of sustainable developmentTechnology Transfer Modelis closely related, mainly includingContract Research, Licensing, Spin-off Incubation Companies, Personnel Exchange and Collaboration, Innovation ClustersSix Pathways for Technology Transfer.

Breakthroughs in cutting-edge technologies have brought infinite possibilities to Germany’s medical innovation industry.

From the perspective of the Nobel Prize in Physiology or Medicine, 16 Germans have been honored with this prestigious award; furthermore, in terms of corporate quality, Germany has given rise to companies includingBayer, Siemens Healthineers, Merck, Boehringer Ingelheim“leaders” in multiple global niche sectors, among others; finally, in terms of incubation capabilities, even a small county town in GermanyTuttlingen, it harborsMore than 400 medical technology companies, including Aesculap (a subsidiary of B. Braun) and KLS Martin (a global leader in the surgical endoscopy market).。

How Exactly Did the Germans Achieve This?

First is the relentless pursuit of original innovations in medical technology. Leveraging a robust scientific research system, German researchers have closely integrated cutting-edge technologies with clinical needs, continuously identifying synergies between the two.

Second, a comprehensive and rigorous system for training medical professionals.German medical practitioners are highly qualified, with 90% holding doctoral degrees. The journey from university enrollment to medical school and ultimately to becoming a clinician takes 12 years, comprising 7 years of doctoral study, 3 years as a resident physician, and 2 years of specialized training.

Third is its globally leading clinical service capability.Germany is the top choice for medical treatment among most celebrities, primarily because Germans have perfected clinical practice. In Germany, the rate of subjective medical errors by physicians is 8%, the lowest globally; the surgical mortality rate is 1.2%, also the lowest worldwide; and the five-year cancer survival rate stands at 86%, ranking among the highest in the world.

Fourth is the substantial market share in the healthcare sector.Germany boasts a wide array of cutting-edge medical equipment and internationally leading healthcare techniques. Reportedly, Germany has consistently held over 95% of the global market share in the medical device sector, spanning from injection supplies and aesthetic surgery consumables to advanced electronic measurement instruments.

Fifth, it possesses a complete industrial chain for medical innovation.Universities and national-level research institutions drive research innovation; patent offices provide professional operations for intellectual property management and monetization; the Business Development Department for Research Innovation assists researchers in preparing business plans; national-level funds offer early-stage non-dilutive support and investment to projects with application value or spin-off startups; seed funds and angel investors step in, followed by venture capital; ultimately, the entities are acquired by large pharmaceutical and industrial companies or go public.

Currently, innovation and translation are becoming the main theme of the development of China's medical industry. This is a consensus in both the scientific research community and the industrial community. However, it must be recognized that China's medical innovation field is still in its early stages, with significant gaps compared to foreign countries in terms of original innovation capabilities and conversion rates.

This is inevitably a resistance, but it is also a driving force.

Therefore, at present, while continuously refining our own innovation capabilities, we urgently need to explore advanced global experiences in medical innovation, so as to break through established paradigms and achieve comprehensive progress in the field of medical innovation.

What, then, can we actually learn from the Germans?

First, break down barriers and establish open innovation.Germans prioritize the dissemination and flow of knowledge in the medical field to optimize research allocation. This is specifically reflected in their establishment of an optimized linking platform among core production factors such as funding, information, technology, and talent, thereby breaking the “closed innovation” model characterized by exclusivity and monopoly, and enabling deep participation from every stakeholder in the healthcare innovation ecosystem.

Secondly, we adhere to innovation as the core driving force, strive for excellence in professionalism, and focus on high-end, precision, and advanced research and development.Regarding innovation in foundational medical technologies, Germany has demonstrated exceptional commitment and achieved excellence across government, research, and corporate sectors. Taking enterprises as an example, many German medical companies have invested substantial funds in building industry-leading laboratories and research facilities, primarily focusing on integrating cutting-edge technologies with clinical pain points.

Finally, establish a platform linking scientific research with industry.In addressing the critical challenge of commercializing scientific research outcomes, Germany has established an internationalized, market-oriented, and information-efficient technology trading platform, with comprehensive implementation across all levels and depths. This enables key stakeholders in the medical innovation ecosystem—including technological innovators, corporate investors, and government agencies—to forge close links and collaborations, thereby facilitating the successful translation of more research achievements into practical applications.

On the arduous path of translating medical innovations into practice, Germany has experienced a tumultuous journey—rising from 0 to 1, then to 100, only to fall back to 0, and finally climbing back to 100. Yet, regardless of the circumstances, Germans have remained consistently passionate and steadfast in their commitment to medical innovation. This unwavering dedication is the core factor that has enabled Germany to stand at the forefront of global medical innovation.